This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Amsden, G. W.
Right arrow Articles by Foulds, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Amsden, G. W.
Right arrow Articles by Foulds, G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 1999, p. 163-165, Vol. 43, No. 1
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Pharmacokinetics in Serum and Leukocyte Exposures of Oral Azithromycin, 1,500 Milligrams, Given over a 3- or 5-Day Period in Healthy Subjects

Guy W. Amsden,1,* Anne N. Nafziger,1 and George Foulds2

Clinical Pharmacology Research Center, Departments of Pharmacy and Medicine, and Research Institute, Bassett Healthcare, Cooperstown, New York,1 and Pfizer Central Research, Pfizer Inc., Groton, Connecticut2

Received 11 March 1998/Returned for modification 23 August 1998/Accepted 20 October 1998

The pharmacokinetics in serum and leukocyte (WBC) exposures of 1,500 mg of oral azithromycin administered as 3-day (500 mg/day, days 1 to 3) and 5-day (500 mg on day 1 and 250 mg/day on days 2 to 5) regimens were compared in 12 healthy volunteers. Serum, polymorphonuclear leukocytes, and mononuclear leukocytes were collected over a 12-day period from the start of each regimen. Results of the study indicate that the exposures of serum and both types of WBCs were similar with both regimens. Drug concentrations in day 12 WBCs were well above the MICs for all relevant community-acquired respiratory tract pathogens. Terminal half-lives in serum obtained by both regimens were essentially equal at 66 h and consistent with past reports. These results indicate that the standard 1,500-mg dose of oral azithromycin can be administered over either 5 or 3 days.

* Corresponding author. Mailing address: Clinical Pharmacology Research Center, Bassett Healthcare, One Atwell Rd., Cooperstown, NY 13326. Phone: (607) 547-3680. Fax: (607) 547-6914. E-mail: guy.amsden{at}bassett.org.

Antimicrobial Agents and Chemotherapy, January 1999, p. 163-165, Vol. 43, No. 1
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • AMSDEN, G. W., GREGORY, T. B., MICHALAK, C. A., GLUE, P., KNIRSCH, C. A. (2007). PHARMACOKINETICS OF AZITHROMYCIN AND THE COMBINATION OF IVERMECTIN AND ALBENDAZOLE WHEN ADMINISTERED ALONE AND CONCURRENTLY IN HEALTHY VOLUNTEERS. Am J Trop Med Hyg 76: 1153-1157 [Abstract] [Full Text]  
  • Liu, P., Allaudeen, H., Chandra, R., Phillips, K., Jungnik, A., Breen, J. D., Sharma, A. (2007). Comparative Pharmacokinetics of Azithromycin in Serum and White Blood Cells of Healthy Subjects Receiving a Single-Dose Extended-Release Regimen versus a 3-Day Immediate-Release Regimen. Antimicrob. Agents Chemother. 51: 103-109 [Abstract] [Full Text]  
  • Beringer, P., Huynh, K. M. T., Kriengkauykiat, J., Bi, L., Hoem, N., Louie, S., Han, E., Nguyen, T., Hsu, D., Rao, P. A., Shapiro, B., Gill, M. (2005). Absolute Bioavailability and Intracellular Pharmacokinetics of Azithromycin in Patients with Cystic Fibrosis. Antimicrob. Agents Chemother. 49: 5013-5017 [Abstract] [Full Text]  
  • Law, C., Amsden, G. W (2004). Single-Dose Azithromycin for Respiratory Tract Infections. The Annals of Pharmacotherapy 38: 433-439 [Abstract] [Full Text]  
  • Amsden, G. W., Baird, I. M., Simon, S., Treadway, G. (2003). Efficacy and Safety of Azithromycin vs Levofloxacin in the Outpatient Treatment of Acute Bacterial Exacerbations of Chronic Bronchitis. Chest 123: 772-777 [Abstract] [Full Text]  
  • Chiu, L. M., Menhinick, A. M., Johnson, P. W., Amsden, G. W. (2002). Pharmacokinetics of intravenous azithromycin and ceftriaxone when administered alone and concurrently to healthy volunteers. J Antimicrob Chemother 50: 1075-1079 [Abstract] [Full Text]  
  • Chin, K. G., McPherson, C. E. III, Hoffman, M., Kuchta, A., Mactal-Haaf, C. (2001). Use of Anti-Infective Agents During Lactation: Part 2--Aminoglycosides, Macrolides, Quinolones, Sulfonamides, Trimethoprim, Tetracyclines, Chloramphenicol, Clindamycin, and Metronidazole. J Hum Lact 17: 54-65 [Abstract]  
  • Amsden, G. W., Gray, C. L. (2001). Serum and WBC pharmacokinetics of 1500 mg of azithromycin when given either as a single dose or over a 3 day period in healthy volunteers. J Antimicrob Chemother 47: 61-66 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»